New #preprint from JAX’s Nadia Rosenthal and researchers at Rocky Mountain Laboratories: “Genetically diverse mouse models of SARS-CoV-2 infection recapitulate clinical variation and cytokine responses in COVID-19”

The preprint, which has yet to be peer reviewed, shows that mice with different genetic backgrounds exhibit highly variable responses to SARS-CoV-2 infection, mirroring the large differences in #COVID19 disease severity seen in humans:

Since the advent of the COVID-19 pandemic, tremendous progress has been made in developing effective vaccines against SARS-CoV-2, the coronavirus that causes COVID-19, and in treating ill patients. Nonetheless, much more needs to be learned about SARS-CoV-2 infectivity and COVID-19 progression to lessen the continuing threat of infection, as the recent emergence and rapid spread of the delta variant has emphasized.

Excerpt of an interview made in May 2021 by “Richard”, who runs the Modern Healthspan YouTube Channel, to George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), among many other responsibilities as a hardwork geneticist.

In this segment, George Church gives his view on whether age reversal in humans and LEV may be achieved during his lifetime.

To watch the entire interview, clic here: https://youtu.be/mztOFAQf8uY

On Wednesday, researchers revealed the first evidence that the approach appears to be working — improving vision for at least some patients with the condition, known as Leber congenital amaurosis, or LCA, a severe form of vision impairment.

---

So doctors genetically modified a harmless virus to ferry the CRISPR gene editor and infused billions of the modified viruses into the retinas of Knight’s left eye and Kalberer’s right eye, as well as one eye of five other patients. The procedure was done on only one eye just in case something went wrong. The doctors hope to treat the patients’ other eye after the research is complete.

Once the CRISPR was inside the cells of the retinas, the hope was that it would cut out the genetic mutation causing the disease, restoring vision by reactivating the dormant cells.

“We’re thrilled about this,” says Dr. Eric Pierce, director of the ocular genomics institute at Massachusetts Eye & Ear and professor of ophthalmology at Harvard Medical School who’s helping run the experiment testing the approach.

The ZyCoV-D vaccine is also the world’s first DNA vaccine against Covid-19.

Like other vaccines, a DNA vaccine, once administered, teaches the body’s immune system to fight the real virus.

ZyCoV-D uses plasmids — or small rings of DNA that contain genetic information — to deliver the jab between two layers of the skin.

ZyCov-D is also India’s first needle-free Covid-19 jab.

It is administered with a disposable needle-free injector, which uses a narrow stream of the fluid to penetrate the skin and deliver the jab to the proper tissue.

---

India has given a boost to its vaccination programme by approving its first vaccine for those under 18.

Leave it to the Japanese to come up with technology-induced fruit

A Tokyo-based startup called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The result was a Sicilian Rouge High GABA which contains high levels of gamma-aminobutyric acid (GABA), an amino acid that is believed to have lower blood pressure and help in relaxation.

The company was able to add high levels of GABA by removing an inhibitory domain within the tomato’s genome to enable the high production of GABA. According to Shimpei Takeshita, President of Sanatech Seed and Chief Innovation Officer of Pioneer EcoScience, the company was given permission to commercialize the genetically altered Sicilian Rouge GABA variety last December. The contract farmers had been growing them ever since and now these tomatoes are finally ready to hit the stores and become a useful product.